Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g. NEAR(recruit, professionals, 20)).
Finds documents with the search term in word versions or composites. The asterisk * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g. lightweight*, *lightweight, *lightweight*).
MBS has evolved from a last-resort intervention to an effective, evidence-based therapeutic modality for obesity and its related medical conditions. The contraindications of the past are the indications of the future.
People who experience stroke or myocardial infarction can continue to receive intravitreal anti-vascular endothelial growth factor therapy without risking increased mortality or morbidity.
Combining ixekizumab with tirzepatide offers additive clinical benefits over ixekizumab alone in the treatment of psoriatic arthritis in patients with overweight or obesity.
Switching people with HIV to an integrase strand transfer inhibitor from a protease inhibitor or non-nucleoside reverse transcriptase inhibitor is associated with an increased risk for diabetes.
FOH is an unsurprising occurrence in youth with T1D and their caregivers and can be a barrier to optimal self-management. This review provides an update of the FOH literature published from 2016 to 2025 for this population.
Insulin remains key to the management of type 2 diabetes, but its role continues to evolve with the arrival of once-weekly regimens presenting new opportunities and challenges. Learn how once-weekly insulin therapy be implemented to optimize patient care.
Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.
Semaglutide use in a man with type 2 diabetes and spinal and bulbar muscular atrophy treated with leuprorelin. Over 2 years glycemic parameters improved and fat mass reduced, with only a minor annual decrease in muscle mass.
A case of fulminant type 1 diabetes in a woman on tislelizumab for lung adenocarcinoma highlights the need for proactive monitoring of fasting glucose, HbA1c, and islet function in people given an immune checkpoint inhibitor.
A 37-year-old woman developed acute encephalopathy and treatment-induced neuropathy of diabetes after 3 months of semaglutide use. Benefits of GLP-1 agonists outweigh the risks, but clinicians should be alert to potential sequelae.
In this special edition of Medicine Matters, we're joined by Dr Gregory Lim, Claire Greenhill, and Sarah Onuora, Chief Editors of Nature Reviews Cardiology, Endocrinology, and Rheumatology, for a look back at the advances in their specialties in 2025.
Find out what caught their attention and why, and what they're looking forward to in 2026.
Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder characterized by insulin resistance and beta-cell dysfunction, often requiring stepwise intensification of therapy to maintain glycemic control [ 1 ]. While basal insulin and GLP-1 …
MicroRNAs (miRNAs) are evolutionarily conserved, short (~ 22 nucleotides), non-coding RNA molecules that function as key post-transcriptional gene expression regulators. [ 1 ]. They perform their regulatory role by base-pairing with complementary …
Atherosclerotic cardiovascular disease (ASCVD) is associated with increased morbidity and mortality in subjects with diabetes mellitus (DM). The present narrative review focuses on the crucial role of platelets in the development and progression …
Pre-existing type 1 or type 2 diabetes mellitus (DM) complicates roughly 1% of pregnancies in the United States (US), with consequences for both baby and mother 1 – 4 . The American Diabetes Association (ADA) recommends that all women with DM, both …
In 2005 the US FDA approved the first GLP-1 medicine for type 2 diabetes, marking the start of a remarkable journey that goes beyond the stimulation of insulin secretion.
Prof. Daniel Drucker gives us a fascinating insight into the early work on GLP-1 and discusses how these medicines are impacting the lives of people with diabetes and obesity. He covers what's known about how they work, treatment duration, side effects, and the role of bariatric surgery, plus what's in the pipeline in terms of drug development and the indications that GLP-1 medicines may be used to treat in the future.
Familiarize yourself with current and emerging ketone monitoring systems and the most useful clinical scenarios in which to use them through our podcasts and e-learning modules. Lower the barriers to effective prevention of diabetic ketoacidosis.
Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.
Refine the application of CGM technology in primary care to enhance the management of type 2 diabetes. Benefit from key updates and experiential learning using CGM devices, and practice your clinical decision-making skills with real cases, vodcasts, and interactive infographics.
Diabetes mellitus (DM) is a chronic metabolic disorder with a rapidly increasing global prevalence, with type 2 diabetes mellitus (T2DM) representing the vast majority of cases [ 1 ]. Among its microvascular complications, diabetic peripheral …
The global prevalence of type 2 diabetes (T2DM), closely related to the parallel epidemic of obesity, is a substantial public health challenge [ 1 ]. The management of T2DM has evolved beyond glycemic control to a comprehensive strategy aimed at …
Obesity has become one of the greatest public health challenges of the twenty-first century with a prevalence that has doubled in adults and quadrupled in adolescents since 1990 (WHO 2019 ). In 2022, 2.5 billion adults and 390 million children and …
Kidney failure is a major public health problem affecting an estimated 844 million people worldwide and of those, 3.9 million are on kidney replacement therapy (KRT) [ 1 ]. Due to the lack of renal registries in sub-Saharan Africa (SSA), there are …
MBS has evolved from a last-resort intervention to an effective, evidence-based therapeutic modality for obesity and its related medical conditions. The contraindications of the past are the indications of the future.
Combining ixekizumab with tirzepatide offers additive clinical benefits over ixekizumab alone in the treatment of psoriatic arthritis in patients with overweight or obesity.
People who experience stroke or myocardial infarction can continue to receive intravitreal anti-vascular endothelial growth factor therapy without risking increased mortality or morbidity.
FOH is an unsurprising occurrence in youth with T1D and their caregivers and can be a barrier to optimal self-management. This review provides an update of the FOH literature published from 2016 to 2025 for this population.